Cancer Immunology – News and Features

This article explores how synthetic biology is revolutionizing therapeutics through engineered cells, precision genetic circuits and AI-driven design, with applications in cancer treatment, vaccine development and next-generation immunotherapies.

Discover how induced pluripotent stem cell technology is solving scale and consistency issues in mesenchymal stem/stromal cell therapy manufacturing and learn about Cynata’s ongoing clinical trials.

Regeneron’s bispecific antibody linvoseltamab, now branded as Lynozyfic, has received conditional approval from the European Commission for relapsed or refractory multiple myeloma. This follows promising results from the LINKER-MM1 trial.

In a Phase 1 clinical trial, a CAR T-cell therapy targeting the CD30 protein has been shown to promote the expansion of memory T cells, leading to durable responses and improved clinical outcomes in patients with refractory CD30+ lymphoma.

Today, our approach to irAE management is predominantly reactive. Clinical guidelines, while increasingly robust, are designed to detect and treat toxicity after it arises. This framework, though necessary, falls short of what is now possible.

A humanized antibody undermines the metabolic checkpoint mediated by CD36 to restore anti-tumor immunity in mouse models of hepatocellular carcinoma as well as liver metastases of colon cancer.

A new study from researchers at Moffitt Cancer Center shows that blocking a chemical process called nitrosylation could make one of the most aggressive forms of melanoma more treatable.

Researchers at Karolinska Institutet have uncovered a unique ability of a special subtype of natural killer cells in the immune system, called adaptive NK cells, to remember ovarian tumors and effectively attack them.

The tumor microenvironment is a harsh environment where metabolic adaptations are key. In this article, we explore how the metabolic constraints of the TME influence cancer and immune cells and dive into the metabolic cross-talk between them.

Traditionally, viruses have been thought of as a burden that cause disease. Now, viruses are being harnessed to tackle diseases that medicines can’t, helping fight cancer, genetic disorders and even infectious diseases.